Biotechnology

IMEIK

IMEIK released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 633.77 M (forecast CNY 769 M), actual EPS CNY 0.99 (forecast CNY 1.05)

IMEIK to Release FY2026 Q1 Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 769 M, EPS CNY 1.05

IMEIK released FY2025 earnings on March 19 After-Market (BJT), actual revenue CNY 2.453 B (forecast CNY 2.567 B), actual EPS CNY 4.28 (forecast CNY 5.0299)

IMEIK released FY2025 Q4 earnings on March 19 After-Market (BJT), actual revenue CNY 587.65 M (forecast CNY 576.47 M), actual EPS CNY 0.6525 (forecast CNY 0.9819)

IMEIK to Release FY2025 Annual Earnings on March 20, 2026 After-Market (BJT), Forecast Revenue CNY 2.563 B, EPS CNY 5.0306

IMEIK released FY2025 Q3 earnings on October 28 After-Market BJT, actual revenue CNY 565.78 M (forecast CNY 660.71 M), actual EPS CNY 1.0097 (forecast CNY 1.4179)

IMEIK released FY2025 9 Months Earnings on October 28 After-Market BJT, Actual Revenue: CNY 1.865 B, Actual EPS: CNY 3.6291

IMEIK to Release FY2025 Q3 Earnings on October 29 After-Market (BJT), Forecast Revenue CNY 660.71 M, EPS CNY 1.4179

IMEIK released FY2025 Q2 earnings on August 18 After-Market (BJT), actual revenue CNY 635.71 M (forecast CNY 840.54 M), actual EPS CNY 1.1494 (forecast CNY 1.7149)

IMEIK released FY2025 Semi-Annual earnings on August 18 After-Market (BJT), actual revenue CNY 1.299 B, actual EPS CNY 2.62

IMEIK to Release FY2025 Semi-Annual Earnings on August 19, 2025 (BJT)

Ameikang Discloses Attitude on Regen Contract Termination

REGEN Authorizes New Company to Distribute AestheFill in Mainland China

Ameikang's Botulinum Toxin Project Submits Additional Materials for Review

Ameikang Responds to Investors on Post-Acquisition Planning and Compliance Issues

Ameikang Responds to PowerFill's Introduction to Domestic Market Plan

Ameyake Terminates ST Suwu's Exclusive Distribution Rights for AestheFill

CICC Sees Positive Progress in Amekang's Acquisition of AESTHEFILL

Ameikang Responds to Crackdown on Fake Aesthetic Products

Korea REGEN Terminates Exclusive Distribution Agreement with Datuo Medical

300896

IMEIK released its 2025 annual report, showing revenue of 2.453 billion yuan, a year-on-year decrease of 19%; net profit of 1.291 billion yuan, a decrease of 34%; and net profit after deducting non-recurring items of 1.1 billion yuan, a decrease of 41%. In 2023, revenue was 2.869 billion yuan, and net profit was 1.858 billion yuan. In the fourth quarter of 2025, revenue was 588 million yuan, and net profit was 200 million yuan. In terms of equity structure, Jian Jun holds 31.09% of the shares

雷帝触网

IMEIK's revenue in 2025 is 2.45 billion, a year-on-year decrease of 19%, with a net profit of 1.1 billion after deducting non-recurring items, down 41%

688366

688363

002612

06826

The National Health Commission reminds that lifestyle beauty institutions, hair salons, nail salons, etc. are not allowed to carry out "light medical beauty" projects. Such projects include non-surgical medical beauty procedures such as injections, phototherapy, and biotechnology, which must be performed by professional medical personnel in institutions with medical beauty service qualifications

Wallstreetcn

HAOHAI BIOTEC

Bloomage Biotech

LANCY

National Health Commission: Beauty institutions, hair salons, nail salons, and other lifestyle-related businesses are strictly prohibited from conducting "light medical beauty" projects

IMEIK's wholly-owned subsidiary, Beijing Nuobote Biotechnology Co., Ltd., recently obtained the "Drug Registration Certificate" for Minoxidil topical solution approved by the National Medical Products Administration. This medication is available in two specifications: 2% and 5%, primarily used for the treatment of androgenetic alopecia and alopecia areata. Minoxidil is a peripheral vasodilator that can stimulate hair growth with long-term use

Zhitong

IMEIK: Subsidiary obtains Minoxidil topical solution "Drug Registration Certificate"

According to the Tianyancha App, on September 24th, Tianjin IMEIK Technology Development Co., Ltd. was established, with Huang Weijun as the legal representative, a registered capital of 100,000 RMB, and a business scope that includes engineering and technology research and experimental development, medical research and experimental development, new material technology research and development, non-residential real estate leasing, cosmetics wholesale, cosmetics retail, information technology consulting services, drug production, and commissioned drug production, among others. Shareholder information shows that the company is wholly owned by IMEIK

IMEIK has established a technology development company in Tianjin

IMEIK announced that on September 10, 2025, its wholly-owned subsidiary IMEIK Hong Kong, together with Aisheng Shourui Limited, established IMEIK International and completed the acquisition of 85% of the shares of South Korea's REGEN Biotech, Inc. for USD 190 million in cash. As of the date of this announcement, the transaction has been fully settled, and the company has effectively obtained 59.5% of the shares of REGEN in South Korea. This acquisition is beneficial for the company to expand its international market and enhance its future profitability and core competitiveness

IMEIK: Acquisition of controlling stake in South Korea's REGEN Biotech, Inc. has been completed

IMEIK stated on the interactive platform that the overseas sales products of REGEN Company currently include two products: AestheFill and PowerFill. Since the new factory of REGEN Company in South Korea began production, the output has been steadily increasing

IMEIK: The production capacity of REGEN's new factory in South Korea is steadily increasing

The pressure on the former leading player in the upstream medical beauty industry has increased.
In the first half of this year, IMEIK's revenue and net profit attributable to the parent company reached 12…

The "Nine Country Kill" of Tongyan Injection is imminent, how will IMEIK face the game?

IMEIK released its semi-annual report for 2025, with operating revenue of 1.299 billion yuan, a year-on-year decrease of 21.59%; net profit attributable to the parent company of 789 million yuan, a year-on-year decrease of 29.57%. The net cash flow from operating activities was 655 million yuan, a year-on-year decrease of 43.06%. Total assets were 8.765 billion yuan, an increase of 5.09% compared to the end of the previous year; net assets attributable to shareholders of the listed company were 7.456 billion yuan, a decrease of 4.37% compared to the end of the previous year. The company plans to distribute a cash dividend of 12 yuan for every 10 shares, and the controlling shareholder and actual controller have not changed

IMEIK 2025 Half-Year Report: Revenue and Profit Both Decline, Plans to Distribute Cash Dividends

IMEIK announced that its holding subsidiary REGEN Biotech, Inc. has received an arbitration application accepted by the Shenzhen International Arbitration Court, involving an amount as high as 1.6 billion yuan. The arbitration was initiated by Datou Medical Devices Co., Ltd., claiming to confirm exclusive agency rights and seeking compensation for losses. The case has not yet been heard, and there is uncertainty regarding its impact on the company's current or future profits. IMEIK and REGEN will actively respond to the lawsuit and fulfill their information disclosure obligations

IMEIK: Major arbitration of its holding subsidiary REGEN Biotech Inc

IMEIK(300896.SZ)